Acid Reflux (GERD) Treatment Guide

About 20% of the U.S. adult population experiences GERD symptoms at least weekly, making it one of the most common reasons patients contact a physician.^[1] Most cases are manageable — often very well — with the right combination of medication and lifestyle adjustment. The challenge is that GERD is also frequently misdiagnosed, overtreated, and confused with conditions that look similar but respond to entirely different approaches.

What I tell patients in the exam room: heartburn is a symptom, not a diagnosis. The burning sensation behind your breastbone after a large meal is the same sensation that can appear in functional heartburn, eosinophilic esophagitis, and early esophageal cancer. Getting the diagnosis right determines everything that follows.

This guide walks through the full clinical picture — from mechanism and diagnosis to medication options, long-term safety considerations, special populations, and when a telehealth visit is the right next step.

What Is GERD — and What Is It Not?

Gastroesophageal reflux disease (GERD) is defined as the condition in which the reflux of gastric contents into the esophagus produces symptoms and/or complications.^[1] Objectively, it is established by abnormal acid exposure on pH monitoring or by characteristic mucosal injury seen at endoscopy.

The lower esophageal sphincter (LES) is the muscular valve between your esophagus and stomach. In GERD, transient relaxations of the LES allow acid and sometimes bile to wash back up. Obesity, hiatal hernia, pregnancy, and certain foods all reduce LES pressure or increase gastric pressure, making reflux more likely.

GERD vs. Functional Heartburn vs. Eosinophilic Esophagitis

Three conditions produce similar symptoms but require different treatment. Getting them straight matters, because functional heartburn does not respond to PPIs and eosinophilic esophagitis (EoE) can progress to permanent scarring if missed.

When a patient doesn't improve after an appropriate PPI trial, this table is where I start. A negative reflux study off PPIs is strong evidence that the problem isn't GERD — and continuing to escalate acid suppression in that setting does more harm than good.

Symptoms and Alarm Signs

Classic GERD presents with heartburn — a burning sensation rising from the stomach toward the chest or throat — and regurgitation, which is the effortless return of stomach contents into the mouth or throat. Symptoms are typically worse after large meals, when lying down, or when bending over.

Many patients also experience less obvious symptoms: chronic cough, hoarseness, throat clearing, or a sensation of something stuck in the throat. These can be signs of laryngopharyngeal reflux (LPR), discussed later in this guide.

The 2022 ACG Clinical Guideline: What Changed

The American College of Gastroenterology published its updated clinical guideline for GERD diagnosis and management in January 2022.^[1] Several recommendations in this update are directly relevant to patients considering treatment.

The guideline also addresses what it calls "optimization" before labeling someone as having refractory GERD. Many patients prescribed twice-daily PPIs for persistent symptoms are simply taking their medication incorrectly — PPIs must be taken 30 to 60 minutes before a meal, not at bedtime. Correcting timing alone resolves symptoms in a meaningful proportion of cases.

Medications for GERD: PPIs, H2 Blockers, and Antacids

Proton Pump Inhibitors (PPIs)

PPIs are the most effective class of medication for GERD. They work by irreversibly blocking the hydrogen-potassium ATPase enzyme (the "proton pump") in gastric parietal cells, reducing acid production by 80–95%. They are the treatment of choice for healing erosive esophagitis and maintaining remission.^[1]

All PPIs in the table above have comparable efficacy when used correctly. Switching from one PPI to another is reasonable if a patient has not responded, but the evidence does not support switching more than once without objective testing to confirm GERD diagnosis.^[1]

H2 Receptor Antagonists (H2RAs)

Famotidine (Pepcid) is the primary H2 blocker used today, following the market withdrawal of ranitidine in 2020. H2RAs work by blocking histamine receptors on gastric parietal cells, reducing acid output by 50–70%. They are less potent than PPIs for healing erosive esophagitis, but they have a faster onset of action — useful for on-demand relief before meals or at bedtime when acid breakthrough is a concern.

Standard famotidine dosing is 20–40 mg once or twice daily. For patients with mild, intermittent symptoms who don't meet criteria for daily PPIs, an H2RA-first approach is reasonable. Tolerance (reduced effectiveness over time) can develop with regular H2RA use, which is one reason PPIs are preferred for sustained symptom control.

Antacids

Antacids — calcium carbonate (TUMS), magnesium hydroxide, or combinations — neutralize stomach acid for 1 to 2 hours. They provide rapid symptomatic relief but have no role in healing esophagitis or preventing complications. Use them for breakthrough symptoms, post-meal discomfort, or when you need fast, short-duration relief. They are safe for most patients, including pregnant women (calcium carbonate is actually preferred in pregnancy since it also provides calcium).

Avoid antacids containing magnesium trisilicate during pregnancy, as high-dose prolonged use is associated with fetal risks. Sodium bicarbonate-containing antacids (some versions of Alka-Seltzer) deliver high sodium loads and should be avoided in patients with hypertension, heart failure, or kidney disease.

Lifestyle Modifications: What the Evidence Actually Supports

The 2022 ACG guideline endorses lifestyle changes as part of GERD management for all patients, though evidence quality varies by intervention.^[1] Here is what the data supports and what I actually tell patients:

Head-of-Bed Elevation

Elevating the head of the bed 6 to 8 inches using a wedge pillow or bed risers reduces nocturnal acid exposure and symptom frequency in patients with nighttime reflux. Simply stacking pillows under your head does not work — it flexes the abdomen, which can worsen reflux. You need a gradual incline from feet to head.

Weight Loss

Obesity — especially central adiposity — increases intra-abdominal pressure and promotes reflux. Among the lifestyle interventions, weight loss has the strongest evidence base. Studies show that losing even 10–15% of body weight reduces GERD symptom frequency and may decrease dependence on medications. If your BMI is above 25 and you have GERD, weight loss should be a central part of the plan, not an afterthought.

Avoiding Late Meals and Recumbency After Eating

Eating within 2 to 3 hours of lying down significantly increases nighttime reflux events. What I recommend to patients: finish dinner at least 3 hours before bed, and if you feel full, stay upright for a while before lying down. This single change makes a meaningful difference in nocturnal symptoms for many people.

Dietary Triggers

Certain foods reduce LES pressure or increase gastric acid: fatty foods, chocolate, caffeine, alcohol, carbonated beverages, citrus, tomatoes, and spicy foods are the most commonly cited.^[1] The evidence for individual triggers varies, and responses are highly personal. My approach: rather than eliminating everything at once, keep a symptom diary for two weeks to identify your specific triggers, then selectively reduce those.

Tobacco and Alcohol Cessation

Smoking reduces LES pressure and impairs esophageal motility. Alcohol both relaxes the LES and can directly irritate esophageal mucosa. Both should be reduced or eliminated in patients with symptomatic GERD.

PPI Step-Down and On-Demand Therapy

One of the most clinically significant changes in the 2022 ACG guideline is the emphasis on deprescribing. In my practice, I see patients who were started on daily PPIs for an appropriate reason years ago and are still on them without any reassessment. That is not good medicine.

The guideline recommends that patients with GERD who do not have erosive esophagitis or Barrett's esophagus — and whose symptoms are controlled — should attempt PPI discontinuation.^[1] The approach:

• Step-down to on-demand dosing: Take a PPI only when symptoms occur rather than every day. This works well for patients with non-erosive reflux disease (NERD).
• Gradual taper: Some patients experience rebound acid hypersecretion after abrupt PPI discontinuation (more studied in healthy volunteers than in GERD patients). Tapering over 2 to 4 weeks before stopping can reduce this.
• Bridge to H2RA: Switching to famotidine on an as-needed basis after stopping a PPI is another reasonable strategy.

Patients with documented LA grade C or D erosive esophagitis, long-segment Barrett's esophagus, or severe symptomatic relapse after PPI discontinuation should remain on maintenance therapy indefinitely at the lowest effective dose. For everyone else, attempting step-down is the right approach.

Long-Term PPI Safety: An Honest Evidence Review

Few topics generate more patient anxiety than PPI safety. Let me be direct about what the evidence shows — and what it doesn't.

Bone Density

Observational studies have found an association between long-term PPI use and modestly increased hip fracture risk (RR approximately 1.20–1.34 in meta-analyses).^[3] The proposed mechanism is impaired calcium absorption due to acid suppression. The ACG guideline states that for patients without risk factors for bone disease, routine bone mineral density monitoring and calcium supplementation are not required solely because of PPI use. For postmenopausal women and others with existing bone density concerns, a conversation about vitamin D and calcium intake is appropriate.

Chronic Kidney Disease

Several large cohort studies and meta-analyses have reported an association between PPI use and increased risk of chronic kidney disease (CKD) and progression to end-stage renal disease. One meta-analysis of over 190,000 patients found a relative risk of 1.28 for CKD and 1.47 for CKD progression with PPI exposure.^[2] These are association studies — they do not establish causality. Confounding (people with more illness take more medications) complicates interpretation. High-quality randomized data confirming a causal link are lacking. For patients on long-term PPIs, annual creatinine monitoring is a reasonable precaution.

Clostridium difficile (C. diff) Infection

This is the one PPI risk with the strongest mechanistic and epidemiologic support. Stomach acid is a barrier to gastrointestinal pathogens, and suppressing it modestly increases susceptibility to C. difficile and other enteric infections.^[4] The FDA has issued a caution regarding this association. For patients hospitalized, on antibiotics, or with prior C. difficile history, unnecessary PPI use should be avoided or discontinued.

Hypomagnesemia

Long-term PPI use can impair magnesium absorption, sometimes severely. The FDA issued a safety communication on this in 2011. Most cases occur after more than one year of use. Patients on long-term PPIs who experience muscle cramps, irregular heartbeat, or fatigue should have magnesium checked. Routine serum magnesium monitoring is recommended for patients expected to remain on PPIs indefinitely.

Dementia and Cognitive Effects

This is a genuinely contested area. Some large cohort studies, including the ARIC Study, have found associations between cumulative PPI use exceeding 4.4 years and a 30% increased risk of incident dementia.^[3] Other well-designed studies have not replicated this finding. Causality is not established. Routine cognitive monitoring is not recommended solely because of PPI use, but it is a reason to avoid unnecessary long-term prescribing, especially in older adults.

Barrett's Esophagus: Screening and Surveillance

Barrett's esophagus occurs when chronic acid exposure causes the normal squamous lining of the lower esophagus to be replaced by columnar epithelium with intestinal metaplasia. It is a precancerous condition — patients with Barrett's have a significantly elevated risk of esophageal adenocarcinoma compared to the general population, though the absolute annual risk remains low (approximately 0.3% per year).

Who Should Be Screened?

The ACG recommends screening endoscopy for patients with chronic GERD (5+ years of symptoms or frequent symptoms) who have multiple risk factors for Barrett's:^[1]

• Age over 50
• Male sex
• White or Hispanic race
• Obesity — especially central adiposity
• Current or former tobacco smoking
• First-degree relative with Barrett's esophagus or esophageal adenocarcinoma

A patient with weekly heartburn who is a 55-year-old White male smoker with abdominal obesity clearly warrants screening. A 32-year-old woman with occasional reflux does not. Screening is a targeted, risk-based decision — not a routine test for everyone with heartburn.

Surveillance After Diagnosis

Once Barrett's is identified, surveillance intervals depend on segment length and degree of dysplasia. Non-dysplastic Barrett's segments under 3 cm are followed every 3 to 5 years; longer segments every 2 to 3 years. Low-grade dysplasia is managed with either endoscopic eradication therapy or intensive surveillance at 6-month intervals. High-grade dysplasia warrants endoscopic eradication therapy — typically radiofrequency ablation.^[5]

Laryngopharyngeal Reflux (LPR): When Reflux Goes Further Up

Laryngopharyngeal reflux (LPR) — sometimes called "silent reflux" — occurs when gastric contents reach the throat and larynx. Unlike GERD, the dominant complaint is not heartburn. Patients with LPR typically describe:

• Chronic throat clearing or coughing
• Hoarseness, especially in the morning
• A globus sensation (feeling of something stuck in the throat)
• Post-nasal drip that hasn't responded to allergy treatment
• Frequent sore throats or laryngitis without infectious cause

Diagnosing LPR is genuinely difficult. Laryngoscopy shows nonspecific signs of laryngeal irritation that overlap with other causes, and pH monitoring has inconsistent sensitivity.^[6] In practice, empiric treatment is both diagnostic and therapeutic: twice-daily PPI therapy for 2 to 3 months, taken 30 to 60 minutes before meals. Response confirms the diagnosis.

The response rate to PPIs is lower in LPR than in typical GERD. Patients need to understand this before starting — a "failed" PPI trial may reflect LPR genuinely not being acid-mediated, not inadequate treatment. Lifestyle changes specific to LPR include avoiding eating within 3 hours of sleep, reducing caffeine, alcohol, and carbonated beverages, and managing any contributing causes of increased intra-abdominal pressure.

GERD During Pregnancy

Heartburn affects up to 80% of pregnant women at some point during gestation. Two factors drive this: progesterone relaxes the lower esophageal sphincter, and the growing uterus increases intra-abdominal pressure, pushing gastric contents upward. Symptoms typically worsen with each trimester and resolve after delivery.

Medication Safety in Pregnancy

Lifestyle measures remain the first approach in pregnancy: smaller more frequent meals, staying upright after eating, avoiding late meals, and sleeping with the head elevated. When medications are needed, step up from antacids to H2RAs to PPIs only as necessary, with OB provider involvement.

Telehealth for GERD: What Works and What Requires Referral

GERD is among the conditions best suited to telemedicine-based management. The initial evaluation — symptom history, alarm feature screening, risk stratification, and PPI trial initiation — can all be conducted through a video visit. Medication refills, dose adjustments, and step-down conversations are efficient and accurate by telehealth.

What I do in a telemedicine GERD visit: I ask about symptom duration, frequency, and character; screen for every alarm feature listed above; assess for Barrett's risk factors; review current medications for drugs that worsen reflux (NSAIDs, calcium channel blockers, bisphosphonates, nitrates); and counsel on lifestyle modifications specific to the patient's situation. The prescription or plan follows from that systematic review.

Telemedicine is not the right setting when endoscopy is indicated. Dysphagia, GI bleeding, weight loss, and suspected Barrett's all require gastroenterology referral for in-person endoscopic evaluation. Telehealth physicians can initiate the referral and coordinate care, but the endoscope itself requires an in-person procedure.

For the majority of patients — those with typical heartburn and regurgitation, no alarm features, and no prior endoscopy indicating complicated disease — a telehealth visit is a fast, clinically appropriate, and cost-effective path to treatment. Many patients get to a diagnosis and a prescription in a single 20-minute video appointment. Phone: 678-956-1855 | Email: contact@teledirectmd.com

When Symptoms Don't Respond: Refractory GERD

Refractory GERD is defined as symptoms that persist despite twice-daily PPI therapy for at least 4 to 8 weeks. Before accepting this label, several common causes of apparent treatment failure should be addressed:

• Incorrect PPI timing: PPIs must be taken 30 to 60 minutes before a meal. Taking them at bedtime or without regard to meals sharply reduces efficacy. This is the most common cause of PPI "failure" I see in practice.
• Incomplete lifestyle modification: Large, late meals the night before a visit can override the best medication regimen.
• Wrong diagnosis: Functional heartburn, EoE, gastroparesis, or achalasia can all mimic GERD. The 2022 ACG guideline recommends upper endoscopy and pH monitoring off PPIs to confirm the diagnosis before escalating treatment.^[1]

Once true GERD is confirmed and medical therapy has been optimized, surgical options including laparoscopic Nissen fundoplication and magnetic sphincter augmentation (LINX device) are effective long-term alternatives for patients with objective evidence of GERD, particularly those with troublesome regurgitation as the dominant symptom. These decisions require in-person surgical and gastroenterological evaluation.

Frequently Asked Questions